PART I Item 1. B usiness. Overview Eledon is a clinical stage biotechnology company using our immunology expertise in targeting the CD40 Ligand (CD40L) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (ALS). Our lead compound in development is tegoprubart, an IgG1, anti-CD40L antibody with high affinity for the CD40L, a well-validated biological target that we believe has broad therapeutic potential. We believe the cent...
Q2 FY2026 — expected 2026-08-14
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-03-19 | 2025-12-31 | 0001193125-26-116164 | EDGAR | 68K words |
| 2025-03-20 | 2024-12-31 | 0000950170-25-042754 | EDGAR | — |
| 2024-03-28 | 2023-12-31 | 0000950170-24-038091 | EDGAR | — |
| 2023-03-30 | 2022-12-31 | 0000950170-23-011011 | EDGAR | — |
| 2022-03-24 | 2021-12-31 | 0001564590-22-011698 | EDGAR | — |
| 2021-03-31 | 2020-12-31 | 0001564590-21-016828 | EDGAR | — |
| 2020-03-17 | 2019-12-31 | 0001564590-20-011260 | EDGAR | — |
| 2019-03-28 | 2018-12-31 | 0001564590-19-009631 | EDGAR | — |
| 2018-04-02 | 2017-12-31 | 0001564590-18-007314 | EDGAR | — |
| 2017-03-03 | 2016-12-31 | 0001193125-17-069741 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-11-14 | 2025-09-30 | 0001193125-25-283275 | EDGAR | 50K words |
| 2025-08-14 | 2025-06-30 | 0001193125-25-180906 | EDGAR | — |
| 2025-05-14 | 2025-03-31 | 0000950170-25-071582 | EDGAR | — |
| 2024-11-12 | 2024-09-30 | 0000950170-24-125622 | EDGAR | — |
| 2024-08-19 | 2024-06-30 | 0000950170-24-098590 | EDGAR | — |
| 2024-05-15 | 2024-03-31 | 0000950170-24-060025 | EDGAR | — |
| 2023-11-09 | 2023-09-30 | 0000950170-23-062203 | EDGAR | — |
| 2023-08-10 | 2023-06-30 | 0000950170-23-041456 | EDGAR | — |
| 2023-05-11 | 2023-03-31 | 0000950170-23-021372 | EDGAR | — |
| 2022-11-14 | 2022-09-30 | 0000950170-22-025007 | EDGAR | — |
| 2022-08-11 | 2022-06-30 | 0000950170-22-016935 | EDGAR | — |
| 2022-05-12 | 2022-03-31 | 0001564590-22-019921 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-03-19 | 0001193125-26-116154 | EDGAR | 3K words |
| 2026-01-02 | 0001193125-26-000968 | EDGAR | — |
| 2025-11-14 | 0001193125-25-283294 | EDGAR | — |
| 2025-11-13 | 0001193125-25-278392 | EDGAR | — |
| 2025-11-07 | 0001193125-25-270286 | EDGAR | — |
| 2025-08-14 | 0001193125-25-180820 | EDGAR | — |
| 2025-08-06 | 0000950170-25-103975 | EDGAR | — |
| 2025-06-12 | 0000950170-25-085588 | EDGAR | — |
| 2025-05-14 | 0000950170-25-071370 | EDGAR | — |
| 2025-04-07 | 0000950170-25-051663 | EDGAR | — |
204 total filings indexed. 172 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001404281 |
| Ticker | ELDN |
| Exchange | Nasdaq |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | DE |
| Website | https://www.eledon.com |
| Listed | 2014-09-17 |
This is the free public profile. For structured JSON with full provenance chain, use the API:
JSON Profile Stock Quote AI Readiness Report